Nathan Yee

Nathan Yee is Senior Director and Head of CMC Strategy & External Technology at Tune Therapeutics, where he oversees integrated CMC development for Tune’s in vivo and ex vivo portfolio programs, including its lead program, TUNE-401. At Tune, Nathan leverages over a decade of experience in biopharma leading teams across discovery, non-clinical assessment, and technical operations to develop epigenetic editing therapies, which modulate gene networks without nicking or cutting DNA – while still remaining precise, tunable, and multiplexable. Prior to Tune, Nathan was the Head of Allogeneic Cell Therapy Platform at Bristol Meyers Squibb where he oversaw de novo platform development for healthy donor-derived and iPSC-based CAR-T approaches. He was also instrumental in the development of BREYANZI while at Juno Therapeutics, from Phase I development through BLA approval. Nathan holds a Ph.D. in Immunology from the University of Washington.